Becker's Healthcare March 24, 2025
Novo Nordisk and United Laboratories International’s subsidiary, United Biotechnology Co. have entered into a potentially $2 billion license agreement for UBT251, a glucagon triple-receptor agonist in early stage clinical development for obesity, Type 2 diabetes and other diseases.
Novo Nordisk will acquire the rights to develop, manufacture and commercialize UBT251 outside of mainland China, Hong Kong, Macau and Taiwan where United Biotechnology will retain the rights, according to a March 24 news release from...
Today's Sponsors
Today's Sponsor